37.01

0.75% -0.28

After Hours: 36.50 -0.51 -1.38%

Kiniksa Pharmaceuticals International Plc (KNSA)

Overview News Price History Option Chain Financials Discussions Forecast

Kiniksa Pharmaceuticals International Plc stock is traded at $37.01, with a volume of 481.64K. It is down -0.75% in the last 24 hours and down -4.69% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Previous Close:

$37.29

Open:

$37.43

24h Volume:

481.64K

Relative Volume:

0.97

Market Cap:

$1.61B

Revenue:

$384.10M

Net Income/Loss:

$-9.07M

P/E Ratio:

-264.36

EPS:

-0.14

Net Cash Flow:

$11.10M

1W Performance:

-4.93%

1M Performance:

-4.69%

6M Performance:

+37.23%

1Y Performance:

+63.83%

1-Day Range:

$36.78

$37.67

1-Week Range:

$35.20

$42.05

52-Week Range:

$17.82

$42.05

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name

Kiniksa Pharmaceuticals International Plc

Sector

Healthcare (1135)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

(781) 431-9100

Address

23 OLD BOND STREET, FLOOR 3, LONDON

Employee

315

Twitter

@kiniksa

Next Earnings Date

2024-10-29

Latest SEC Filings

KNSA's Discussions on Twitter

Compare KNSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KNSA Kiniksa Pharmaceuticals International Plc	37.01	2.76B	384.10M	-9.07M	11.10M	-0.14
ZTS Zoetis Inc	144.09	63.86B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.44	41.80B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.27	40.88B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	20.48	22.98B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	445.43	19.53B	3.08B	1.24B	1.07B	25.61

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-29-25	Initiated	TD Cowen	Buy
Mar-13-25	Initiated	Citigroup	Buy
Sep-13-24	Initiated	Jefferies	Buy
May-03-24	Initiated	Wells Fargo	Overweight
Jun-29-20	Reiterated	BofA Securities	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Mar-11-19	Initiated	Barclays	Overweight
Dec-12-18	Reiterated	Wedbush	Outperform
Jun-19-18	Initiated	JMP Securities	Mkt Outperform

View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

Oct 31, 2025

Equities Analysts Offer Predictions for KNSA FY2025 Earnings - MarketBeat

Oct 31, 2025

Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows - MSN

Oct 31, 2025

Oct 30, 2025

Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock - Investing.com

Oct 30, 2025

Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock By Investing.com - Investing.com UK

Oct 30, 2025

New Strong Sell Stocks for Oct. 30th - The Globe and Mail

Oct 30, 2025

Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage - Seeking Alpha

Oct 30, 2025

Oct 29, 2025

Goldman Sachs Raises Target Price for Kiniksa Pharmaceuticals (K - GuruFocus

Oct 29, 2025

Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World

Oct 29, 2025

Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win - Yahoo! Finance UK

Oct 29, 2025

Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus

Oct 29, 2025

Oct 28, 2025